
UniSA Ventures is the technology commercialisation and investment management company of the University of South Australia (UniSA). We work with UniSA staff and students to protect and manage the results of their research.






The Adelaide China Biotech Investment Fund is backed by a group of private investors based in Nanjing, China, underwritten by the Bank of Nanjing.

The technology is designed to dramatically increase the accuracy of identifying the early spread of solid tumour cancers,

UniSA Ventures' spin-out Myriota, today announced that former NASA astronaut and ex-DARPA Deputy Director of the Tactical Technology Office, Pamela Melroy, has joined its board as a non-executive director.
We offer a range of commercialisation services for UniSA staff and students.
We can connect your organisation with UniSA's innovative technologies and world-class research capabilities.